A multicenter, open-label, single ascending dose, dose-ranging phase I/II study of TX200.
Phase of Trial: Phase I/II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs TX-200 (Primary)
- Indications Transplant rejection
- Focus Adverse reactions; First in man
- Acronyms STEADFAST
- 19 Nov 2019 According to a Sangamo Therapeutics media release, the company expects to open the first clinical site in 2020.
- 19 Nov 2019 According to a Sangamo Therapeutics media release, that the United Kingdom's (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy.
- 07 Aug 2019 According to a Sangamo Therapeutics media release, company is remain on track to file CTA in 2019.